Disc Medicine, Inc. (IRON) Stock Price & Analysis
Disc Medicine, Inc. (IRON) closed at USD 56.65 on Thursday, October 15, 2026, up 1.63% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 55.74; the Oct 15, 2026 session ranged USD 55.95–58.09 on volume of 691,678 shares. Market capitalization is $2.17B, with a 52-week range of USD 40–99.5 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IRON.md
Key facts (IRON)
- Analysts: Buy (mean 1.92 on a 1–5 scale) (13 analysts), mean target USD 103.17 (range 83–128).
- Total return with dividends: 1Y -23.8% vs S&P 500 +18.1%; 5Y -49.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.71, revenue estimate $0K.
Analysts (IRON)
Consensus Buy (mean 1.92 on a 1–5 scale), 13 analysts; mean target USD 103.17 (low 83, high 128).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-16 | Wells Fargo | Target raised | Overweight | $79 → $86 |
| 2026-09-10 | Wedbush | Reiterated | Outperform | $100 |
| 2026-09-02 | Wedbush | Target raised | Outperform | $88 → $100 |
| 2026-08-06 | HC Wainwright & Co. | Target raised | Buy | $118 → $120 |
Total return (dividends reinvested) (IRON)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -23.8% | -49.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -23.9% | -12.7% |
| Volatility (annualized) | 54.0% | 74.2% |
| Max drawdown | -40.8% (Nov 2025→Oct 2026) | -83.3% (Oct 2021→Jan 2023) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 56.65 |
|---|---|
| Change | ▲ 1.63% (up) |
| Previous Close | USD 55.74 |
| Open | USD 56.66 |
| Day Range | USD 55.95 – 58.09 |
| 52-Week Range | USD 40 – 99.5 |
| Volume | 691,678 shares |
| Market Cap | $2.17B |
| Exchange | NGM |
Technical Analysis (IRON)
Nexqual's technical model rates IRON "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.35 (oversold) |
| vs SMA50 | Below (USD 71.92) |
| MACD | -4.08 (negative) |
Analyst Ratings (IRON)
Wall Street analysts rate IRON "Buy" based on 13 analysts, with a mean price target of USD 103.17 (range USD 83–128), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 103.17 |
| High Target | USD 128 |
| Low Target | USD 83 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (IRON)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -1.71 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.54 vs est -1.77 ▲ beat |
| 2026-03-31 | USD -1.65 vs est -1.73 ▲ beat |
| 2025-12-31 | USD -1.62 vs est -1.7 ▲ beat |
| 2025-09-30 | USD -1.77 vs est -1.46 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (IRON)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -39.08% |
| Debt / Equity | 0.09 |
| Current Ratio | 24.14 |
| Total Cash | $717.75M |
| Total Debt | $60.86M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (IRON)
Nexqual rates Disc Medicine, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $718M cash vs $61M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$198M (TTM) |
| Efficiency | Critical — ROE -39%, ROA -24.0% |
Ownership (IRON)
| Insider Ownership | +7.84% |
|---|---|
| Institutional Ownership | +114.11% |
| Shares Outstanding | 38.39M |
| Float | 32.91M |
| Short % of Float | +22.08% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (IRON)
Disc Medicine, Inc. is led by John D. Quisel Esq. (age 54), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO, President & Director | John D. Quisel Esq. (age 54) |
|---|---|
| Executive Chairman | Donald William Nicholson (age 67) |
| Chief Financial Officer | Jean M. Franchi (age 59) |
Major Backers & Investors (IRON)
Notable institutional backers of Disc Medicine, Inc. include FMR, LLC, Fidelity, JPMorgan, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.75% |
| Fidelity | 7.77% |
| JPMorgan | 6.58% |
| RA Capital Management, L.P. | 6.38% |
| Price (T.Rowe) Associates Inc | 4.88% |
| Wellington Management | 4.54% |
| Vestal Point Capital, LP | 4.04% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.33% |
| State Street | 6.16% |
| Vanguard Group | 6.1% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt